1、抗肿瘤抗体药物的研发。

2、抗耐药菌的抗菌药物的研究。

3、计算机辅助药物设计。

1、主持国家自然科学基金青年项目一项（项目名称：以DLL4及VEGF为双靶点的双特异性抗体的抗肿瘤活性及机制研究）；

2、主持江苏省自然科学基金青年项目一项（项目名称：达托霉素生物合成基因的代谢调控及其高产基因工程菌的构建）。

1）Yuhong Zhao , Shijing Wang, Wenyi Fei, Yuqi Feng, Le Shen, Xinyu Yang , Min Wang* and Min Wu*. Prediction of anticancer peptides with high efficacy and low toxicity by hybrid model based on 3D structure of peptides[J]. International Journal of Molecular Sciences. 2021, 22(11):5630.

2）Shijing Wang; Hui Wen; Wenyi Fei, Yuhong Zhao, Yuqi Feng, Lu Kuang, Min Wang*, Min Wu*. Two engineered site-specific antibody-drug conjugates, HLmD4 and HLvM4, have potent therapeutic activity in two DLL4-positive tumour xenograft models[J], American Journal of Cancer Research, 2020, 10(8)：2387-2408.

3）Rihong Zhou, Shijing Wang, Hui Wen, Min Wang∗, Min Wu∗. The bispecific antibody HB-32, blockade of both VEGF and DLL4 shows potent anti-angiogenic activity in vitro and anti-tumor activity in breast cancer xenograft models[J], Experimental Cell Research, 2019, 380(2): 141-148.

4）Shijing Wang, Rihong Zhou, Fumou Sun, Renjie Li, Min Wang*, Min Wu** .The two novel DLL4-targeting antibody-drug conjugates MvM03 and MGD03 show potent anti-tumour activity in breast cancer xenograft models, Cancer Letters, 2017, (409) 125-136.

5) Zhuobin Xu, Zegen Wang, Xuelian Jia, Luxuan Wang, Zhiguo Chen, Shijing Wang, Min Wang*, Juan Zhang*, Min Wu*. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth，Cancer Letters, 2016, (372) 118–127.

6）Xuelian Jia, Wenyi Wang, Zhuobin Xu, Shijing Wang, Tong Wang, Min Wang*, Min Wu*. A humanized anti-DLL4 antibody promotes dysfunctional angiogenesis and inhibits breast tumor growth,  Scientific Reports, 2016, 6:27985